Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.
Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.
Vir Biotechnology reported Q3 2024 financial results, highlighting a transformational quarter marked by the closing of an exclusive worldwide licensing agreement with Sanofi for three clinical-stage dual-masked T-cell engagers. The company reported a net loss of $(213.7) million, or $(1.56) per share. Total revenues were $2.4 million, with cash and investments of $1.19 billion. Key developments include promising Phase 2 SOLSTICE data in chronic hepatitis delta, appointment of Jason O'Byrne as CFO, and a strategic restructuring reducing workforce by 25%. The company updated its GAAP operating expense guidance to $660-680 million for 2024.
Vir Biotechnology (Nasdaq: VIR) has announced that it will provide a corporate update and report its third quarter 2024 financial results on October 31, 2024. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The financial results and corporate update will be released via a press release after market close and will be accessible on the company's website. Interested parties can join the conference call through a webcast or by dialing in. A recorded version of the call will be available on the website approximately two hours after the event and will be archived for 30 days.
Vir Biotechnology (NASDAQ:VIR) announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating tobevibart and elebsiran for the potential treatment of chronic hepatitis delta at AASLD's The Liver Meeting® 2024. The company will present an oral presentation on the Week 24 primary endpoint analysis of the SOLSTICE trial, along with five poster presentations.
The posters will cover topics including:
- Pharmacokinetics and safety of elebsiran in participants with moderate renal impairment
- Dose-dependent effects of tobevibart on Hepatitis B Surface Antigen composition
- Safety profile of tobevibart and elebsiran for chronic hepatitis B and delta
- Evidence supporting surrogate endpoints and fibroscan in hepatitis D infection
- Economic burden among HDV-infected patient segments
These presentations aim to highlight progress in Vir's hepatitis delta and hepatitis B clinical programs, as well as provide insights into disease burden.
Vir Biotechnology, Inc. (NASDAQ:VIR) has announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The event is scheduled for Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.
A live webcast of the fireside chat will be available under the Events & Presentations section in the Investors area of the Vir website at www.vir.bio. The webcast will remain archived on the site for 30 days following the event.
Vir Biotechnology (Nasdaq: VIR) has appointed Jason O'Byrne as Executive Vice President and Chief Financial Officer, effective October 2, 2024. O'Byrne brings over 20 years of experience in finance and operations to Vir. He joins from Caribou Biosciences, where he served as CFO, and previously held senior roles at Audentes Therapeutics and Genentech. O'Byrne's expertise spans capital allocation, corporate strategy, and operational execution.
CEO Marianne De Backer praised O'Byrne's exceptional leadership and proven track record in financial strategy across public companies. O'Byrne expressed excitement about joining Vir as it expands into oncology and continues work in infectious diseases. His appointment aims to support Vir's mission of advancing innovative antibody therapeutics.
Vir Biotechnology (Nasdaq: VIR) has closed its exclusive worldwide license agreement with Sanofi, initially announced on August 1, 2024. This strategic deal grants Vir exclusive rights to three clinical-stage masked T-cell engagers (TCEs) and the PRO-XTEN masking platform for oncology and infectious disease applications. The agreement includes:
1. SAR446309: A dual-masked HER2-targeted TCE in phase 1 for metastatic HER2+ tumors.
2. SAR446329: A dual-masked PSMA-targeted TCE in phase 1 for metastatic castration-resistant prostate cancer.
3. SAR446368: A dual-masked EGFR-targeted TCE with an active IND, phase 1 study expected to begin in Q1 2025.
Key Sanofi employees with TCE expertise will join Vir. The company plans to provide further details at its upcoming R&D Day in November.
Vir Biotechnology (NASDAQ: VIR) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's CEO, Marianne De Backer, M.Sc., Ph.D., MBA, is scheduled to take part in a fireside chat on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City.
Investors and interested parties can access a live webcast of the fireside chat through the Events & Presentations section of Vir Biotechnology's website at www.vir.bio. The webcast will remain archived on the site for 30 days following the event, allowing those unable to attend the live session to catch up on the discussion.
Vir Biotechnology (Nasdaq: VIR) reported Q2 2024 financial results and announced a strategic restructuring. Key highlights include:
1. Positive preliminary Phase 2 data for chronic hepatitis delta treatment
2. FDA IND clearance and Fast Track Designation for tobevibart and elebsiran
3. Exclusive license agreement with Sanofi
4. Strategic workforce restructuring, reducing headcount by 25%
5. $1.43 billion in cash and investments as of June 30, 2024
6. Q2 2024 revenues of $3.1 million, down from $3.8 million in Q2 2023
7. Net loss of $(138.4) million, or $(1.02) per share
8. Lowered full-year 2024 operating expense guidance to $580-$610 million
Vir Biotechnology (Nasdaq: VIR) has entered an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. The deal includes SAR446309 (HER2-targeted), SAR446329 (PSMA-targeted), and SAR446368 (EGFR-targeted) TCEs. This strategic move aligns with Vir's mission of powering the immune system and aims to address treatment-associated toxicity in cancer therapeutics.
The proprietary masking platform potentially increases the therapeutic index and mitigates toxicities associated with systemic immune activation. Key employees with expertise in TCEs will join Vir upon regulatory clearance. Vir will make an upfront payment to Sanofi, which is also eligible for future milestone payments and tiered royalties on worldwide net sales.
Vir Biotechnology (Nasdaq: VIR) has announced that it will release its second quarter 2024 financial results on August 1, 2024. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can access the financial results via a press release that will be available on the company's website after market close. The conference call can be accessed through a webcast on Vir's website or by dialing in using the provided toll-free numbers. A recorded version of the call will be available on the website approximately two hours after the event and will be archived for 30 days.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
